Axial and Appendicular Bone Mineral Density in Patients with Long-Term Deficiency or Excess of Calcitonin

New England Journal of Medicine

Volumn 317, Issue 9, 1987, Pages 537-541

  Hurley, Daniel L ^a,b   Tiegs, Robert D ^a,b   Wahner, Heinz W ^a,b   Heath, Hunter ^a,b  

^a Dept Pediat Louisiana Stt U   (United States)

^b MAYO CLINIC COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; BONE; BONE ATROPHY; CALCITONIN BLOOD LEVEL; CLINICAL ARTICLE; ENDOCRINE SYSTEM; HUMAN; HYPERCALCITONINEMIA; PHOTON ABSORPTIOMETRY; PRIORITY JOURNAL; THYROID CARCINOMA; THYROIDECTOMY;

EID: 0023192873     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJM198708273170904     Document Type: Article

References (37)

1. Austin LA, Heath H III. Calcitonin: physiology and pathophysiology. N Engl J Med 1981; 304: 269–78.
2. Chambers TJ, Moore A. The sensitivity of isolated osteoclasts to morphological transformation by calcitonin. J Clin Endocrinol Metab 1983; 57: 819–24.
3. Milhaud G, Benezech-Lefevre M, Moukhtar MS. Deficiency of calcitonin in age related osteoporoses. Biomedicine 1978; 29: 272–6.
4. Taggart HM, Chesnut CH III, Ivey JL, et al. Deficient calcitonin response to calcium stimulation in postmenopausal osteoporosis? Lancet 1982; 1: 475–8.
5. Stevenson JC. Regulation of calcitonin and parathyroid hormone secretion by oestrogens. Maturitas 1982; 4: 1–7.
6. Zséli J, Szücs J, Steczek K, et al. Decreased calcitonin reserve in accelerated postmenopausal osteoporosis, Horm Metab Res 1985; 17: 696–7.
7. Leggate J, Farish E, Fletcher CD, McIntosh W, Hart DM, Sommerville JM. Calcitonin and postmenopausal osteoporosis. Clin Endocrinol (Oxf) 1984; 20: 85–92.
8. Tiegs RD, Body JJ, Wanner HW, Barta J, Riggs BL, Heath H III. Calcitonin secretion in postmenopausal osteoporosis. N Engl J Med 1985; 312: 1097–100.
9. Melvin KEW, Tashjian AH Jr, Bordier P. The metabolic significance of calcitonin-secreting thyroid carcinoma. In: Frame B, Parfitt AM, Duncan H, eds. Clinical aspects of metabolic bone disease: proceedings of the International Symposium on Clinical Aspects of Metabolic Bone Disease, Henry Ford Hospital, Detroit, Mich., June 26–29, 1972. Amsterdam: Excerpta Medica, 1973:193–201. (International Congress Series no. 270.)
10. Gruber HE. Ivey JL, Baylink DJ. et al. Long-term calcitonin therapy in postmenopausal osteoporosis. Metab Clin Exp 1984; 33: 295–303.
11. McDermott MT, Kidd GS, Blue P, Ghaed V, Hofeldt FD. Reduced bone mineral content in totally thyroidectomized patients: possible effect of calcitonin deficiency. J Clin Endocrinol Metab 1983; 56: 936–9.
12. Sizemore GW, Heath H III, Carney JA. Multiple endocrine neoplasia type 2. Clin Endocrinol Metab 1980; 9: 299–315.
13. Riggs BL, Wanner HW, Dunn WL, Mazess RB, Offord KP, Melton LJ III. Differential changes in bone mineral density of the appendicular and axial skeleton with aging: relationship to spinal osteoporosis. J Clin Invest 1981; 67: 328–35.
14. Body J-J, Heath H III. Estimates of circulating monomeric calcitonin: physiological studies in normal and thyroidectomized man. J Clin Endocrinol Metab 1983; 57: 897–903.
15. Tiegs RD. Body J-J, Barta JM, Heath H III. Secretion and metabolism of monomeric human calcitonin: effects of age, sex, and thyroid damage. J Bone Miner Res 1986; 1: 339–49.
16. Husdan H, Rapoport A, Locke S. Influence of posture on the serum concentration of calcium. Metab Clin Exp 1973; 22: 787–97.
17. Wahner HW, Dunn WL, Riggs BL. Noninvasive bone mineral measurements. Semin Nucl Med 1983; 13: 282–9.
18. Wahner HW, Riggs BL, Beabout JW. Diagnosis of osteoporosis: usefulness of photon absorptiometry at the radius. J Nucl Med 1977; 18: 432–7.
19. Heath H III, DiBella FP. Reduced-volume radioimmunoassays for parathyrin and calcitonin in serum, for use in pediatric and small-animal studies. Clin Chem 1978; 24: 1833–5.
20. Heath H III, Sizemore GW. Radioimmunoassay for calcitonin. Clin Chem 1982; 28: 1219–26.
21. Sizemore GW, Heath H III. Immunochemical heterogeneity of calcitonin in plasma of patients with medullary thyroid carcinoma. J Clin Invest 1975; 55: 1111–8.
22. Seth J, Kellett HA, Caldwell G, et al. A sensitive immunoradiometric assay for serum thyroid stimulating hormone: A replacement for the thyrotrophin releasing hormone test? Br Med J 1984; 289: 1334–6.
23. Martino E, Bambini G, Bartalena L, et al. Human serum thyrotrophin measurement by ultrasensitive immunoradiometric assay as a first-line test in the evaluation of thyroid function. Clin Endocrinol (Oxf) 1986; 24: 141–8.
24. Arnaud CD, Tsao HS, Littledike T. Radioimmunoassay of human parathyroid hormone in serum. J Clin Invest 1971; 50: 21–34.
25. Gallagher JC, Riggs BL, Jerpbak CM, Arnaud CD. The effect of age on serum immunoreactive parathyroid hormone in normal and osteoporotic women. J Lab Clin Med 1980; 95: 373–85.
26. Seeman E, Wahner HW, Offord KP, Kumar R, Johnson WJ, Riggs BL. Differential effects of endocrine dysfunction on the axial and the appendicular skeleton. J Clin Invest 1982; 69: 1302–9.
27. Rosenfeld MG, Amara SG, Birnberg NC, Mermod J-J, Murdoch GH, Evans RM. Calcitonin, prolactin, and growth hormone gene expression as model systems for the characterization of neuroendocrine regulation. Recent Prog Horm Res 1983; 39: 305–51.
28. Nelkin BD, Rosenfeld KI, de Bustros A, Leong SS, Roos BA, Baylin SB. Structure and expression of a gene encoding human calcitonin and calcitonin gene related peptide. Biochem Biophys Res Commun 1984; 123: 648–55.
29. Ittner J, Dambacher MA, Born W, et al. Diagnostic evaluation of measurements of carboxyl-terminal flanking peptide (PDN-21) of the human calcitonin gene in human serum. J Clin Endocrinol Metab 1985; 61: 1133–7.
30. Roos BA, Fischer JA, Pignat W, Alander CB, Raisz LG. Evaluation of the in vivo and in vitro calcium-regulating actions of noncalcitonin peptides produced via calcitonin gene expression. Endocrinology 1986; 118: 46–51.
31. Chambers TJ, McSheehy PMJ, Thomson BM, Fuller K. The effect of calcium-regulating hormones and prostaglandins on bone resorption by osteoclasts disaggregated from neonatal rabbit bones. Endocrinology 1985; 116: 234–9.
32. Fallon MD, Perry HM III, Bergfeld M, Drake D, Teitelbaum SL, Avioli LV. Exogenous hyperthyroidism with osteoporosis. Arch Intern Med 1983; 143: 442–4.
33. Krølner B, Vesterdal Jørgensen J, Nielsen SP. Spinal bone mineral content in myxoedema and thyrotoxicosis: effects of thyroid hormone(s) and antithyroid treatment. Clin Endocrinol (Oxf) 1983; 18: 439–46.
34. Toh SH, Claunch BC. Brown PH. Effect of hyperthyroidism and its treatment on bone mineral content. Arch Intern Med 1985; 145: 883–6.
35. Kaplan EL, Sizemore GW, Peskin GW, Jaffe BM. Humoral similarities of carcinoid tumors and medullary carcinomas of the thyroid. Surgery 1973; 74: 21–9.
36. Barrowman JA, Bennett A, Hillenbrand P, Rolles K, Pollock DJ, Wright JT. Diarrhoea in thyroid medullary carcinoma: role of prostaglandins and therapeutic effect of nutmeg. Br Med J 1978; 3: 11–12.
37. Keusch G, Binswanger U, Dambacher MA, Fischer JA. Ectopic ACTH syndrome and medullary thyroid carcinoma. Acta Endocrinol (Copenh) 1977; 86: 306–16.